Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chemocoxib A is an experimental small molecule therapeutic belonging to the coxib class of selective cyclooxygenase-2 (COX-2) inhibitors. Developed primarily for antineoplastic applications, it is designed to exploit the overexpression of COX-2 in various solid tumors, particularly breast cancer. In research settings, chemocoxib A is frequently co-encapsulated with imaging agents like fluorocoxib Q (FQ) within reactive oxygen species (ROS)-responsive polymeric micellar nanoparticles. This delivery system allows for the targeted release of the drug in the high-oxidative-stress environment of the tumor microenvironment, enabling both the visualization of drug delivery and the inhibition of tumor growth through COX-2-dependent pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chemocoxib A.